David Jimenez Lopez Email & Phone Number

Boston, Ma, Us

Princeton, New Jersey, United States

Reporting directly to Moderna CEO, lead the U.S. Commercial organization..Built Moderna’s Commercial Organization, inclusive of Operations, Pricing, Contracting, Access, Payers, Public Policy, Governmental Affairs, Marketing, Key Account Management, and Communications, selling to over 30k customers; retail, IDN’s, Health Systems, Government, etc.Successfully commercializing COVID-19 vaccines for the first time in Moderna history, significantly increasing market share of vaccine from 36% (during Emergency Use Authorization) to 48% (after commercial launch in Sep 2023).Enabled rapid scaling of sales by recruiting and empowering a high-performing team of “unicorns” to build departments, and execute a flexible and individualized experience strategy for payers, providers, hospitals and more.

Full P&L responsibility for the Immunology portfolio in the U.S., generating $12B in revenue. Worked closely with R&D and M&A on actual and future pipeline. Portfolio includes: STELARA® (ustekinumab), REMICADE® (infliximab), TREMFYA® (guselkumab), SIMPONI® (golimumab) and SIMPONI ARIA®.Managed a team of >2000 people in Commercial, Medical, Clinical, Marketing, Operations, Patient Support, etc. with $12B in revenue.Managed the portfolio and new launches across Rheum, Gastro, and Derm in areas including Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis & Plaque Psoriasis.

New Jersey, United States

Full P&L responsibility generating $2B+ in revenue. Worked closely with R&D and M&A on actual and future pipeline. Portfolio: OPSUMIT® (macitentan) and UPTRAVI® (selexipag) and TRACLEER® and VELETRI®.Led $31B integration of Actelion by J&J for $31B. Moved the Headquarters from San Francisco to New Jersey, retaining key talent, minimizing business impact, and delivering business plan commitments in terms of growth and market share.Led the creation of Rare Disease patient strategy and market preparation for the launch of gene therapies, targeting patients with the inherited retinal disease (IRD) X-linked retinitis pigmentosa (XLRP).

United States

Full P&L responsibility generating +2B in revenue and oversaw a team of 200+ across Medical, Clinical, Marketing, operations, sales, etc.Managed the full infectious diseases portfolio, with a focus on HIV therapies. Portfolio: SYMTUZA® (darunavir/cobicistat/emtricitabine/tenofovir alafenamide tablets), PREZCOBIX® (darunavir/cobicistat), PREZISTA® (darunavir), EDURANT® (rilpivirine), INTELENCE® (etravirine), SIRTURO® (bedaquiline).Reversed YoY declines, and led launch of SYMTUZA®, single tablet Darunavir regimen for HIV.R&D, M&A and partnership development. Led partnership with ViiV on the commercialization of the first long-acting injectable for HIV: CABENUVA (Cabotegravir/Rilpivirine).

Puerto Rico

Full P&L Responsibility for the whole Janssen portfolio in Puerto Rico: Oncology (Solid and Hema), Immunology (Rheum, Gastro and Derm), Cardiovascular & Metabolic (Diabetes, DVT and PE), Infectious diseases (HIV) and Neuroscience (Schizophrenia & Mood).Grew market share, outperforming the continental U.S. market by evolving the go-to-market model strategy and implementing key management changes resulting in increasing the market share across all therapies.Provided agile and steady leadership during Hurricane Maria crisis in 2017, Puerto Rico’s largest crisis, supporting the +5k employees, while creating new processes so that HCP’s and patients could access our medicines.

Dubai

Full P&L responsibility for the region for LifeScan (Glucometers) and Animas (Insulin Pumps).Portfolio Management across 50 countries either directly or through distributors and partners. Developed region-specific strategies working with country business unit leaders.Doubled business In 3 years, outpacing market growth rate by creating partnerships and leveraging the whole organization and applying best practices catered to individual markets.Created strong partnerships with health care providers, retail and government, including developing awareness and education programs to diagnose, treat, and create healthy habits for diabetes.Opened new markets in Turkey, Iraq, Pakistan and Tunisia maintaining the highest level of compliance and Ethics.

United States

Portfolio includes absorbable and non-absorbable sutures, hernia meshes, and topical adhesives.Global strategy lead, identifying and leveraging best practices, transferring success models across countries globally in areas including Launch Excellence, Strategic Pricing, Health Economics & Reimbursement, and Sale Force Effectiveness.

Responsible for leading and executing the strategy of the Sutures portfolio business across Europe Middle East and Africa.Strategy lead for diverse markets, creating country and region-specific strategies, collaborating with countries to maximize growth and market competitiveness of the actual portfolio and product launches.Reversed decline in sales, returning region to growth.Launched the entire Antimicrobial Sutures portfolio in EMEA, collaborating with European societies to endorse the value of the portfolio like NICE (UK), Hygienist Society (Germany), European Society of Surgical Infection, etc.

Responsible for the hernia and topical adhesives portfolio in Spain. Led the team and created and executed the strategy that delivered the fastest growth in EMEA, becoming a benchmark strategy for the whole company worldwide.

Parapharmacy Franchise Company

Pharmacist, Pharmacy

Advance Management Program (Amp), Business Administration And Management, General, Amp

Mba, Mba

Healthcare